Breast Cancer: Page 2

Netherlands study finds blood protein level changes two years prior to breast cancer diagnosis
The study found that prior to being diagnosed with breast cancer, women may experience changes in the levels of certain proteins found in the bloodstream, leading to the potential for early detection using blood tests.
November 16, 2022
Breast Mammo Social
Delphi Diagnostics announces use of genetic test in ongoing breast cancer trial
While the test has been used to assess tumors in the ongoing trial for the past year, it will now additionally be used for adaptive randomization of patients whose biomarker profiles show that they may benefit from endocrine therapy.
October 27, 2022
Cancer Cell Target2 Resized
Prelude Dx to present clinical utility data for DCIS risk assessment test
DCISionRT predicts radiation therapy benefit through a risk assessment test for patients with ductal carcinoma in situ (DCIS).
October 21, 2022
Breast Cancer Social
Boston Cell Standards nabs FDA clearance for IHC test panel to evaluate breast cancers
Boston Cell Standards on Thursday announced that the FDA has granted 510(k) clearance for the company’s IHControls panel for evaluating breast cancers.
October 6, 2022
Breast Cancer
Roche gets FDA approval for metastatic breast cancer CDx
The Pathway anti-HER2 (4B5) test is now FDA-approved for use in the assessment of metastatic breast cancer patients who may be eligible for Enhertu, an HER2-directed antibody drug conjugate.
October 4, 2022
Breast Cancer2 Social
At-home test spots biomarkers related to breast abnormalities
Namida Lab has developed the Auria diagnostic test, which provides a personalized score and classification that corresponds to an urgency level, indicating when a mammogram should be scheduled. The laboratory-developed test is available to women between the ages of 33 and 85 with an average risk of developing breast cancer, regardless of their breast tissue density.
September 13, 2022
2022 06 10 18 54 3241 Test Tube Liquid Sample 400
Most Popular
Researchers find hidden bacteria that pose antimicrobial resistance risk to hospital patients
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
SD Biosensor, SJL Partners complete acquisition of Meridian Bioscience
OIG report outlines challenges with CDC-supported COVID-19 vaccination programs
Roche reports flat diagnostics revenue growth for 2022
Duke University developing blood test to detect osteoarthritis progression in the knee
Natera presents colorectal, breast cancer data at ESMO 2022
One abstract, related to the Bellini trial, examined the potential clinical utility of circulating tumor DNA (ctDNA) in assessing the response to neoadjuvant immunotherapy in patients with early-stage (I-II) triple-negative breast cancer (TNBC).
September 12, 2022
2019 07 27 00 04 3609 Breast Cancer Cell 400
Ibex announces study results for breast pathology platform
Ibex chief medical officer Dr. Judith Sandbank reported at the congress 100% sensitivity and specificity for pathologists diagnosing breast cancer using the platform.
September 8, 2022
2021 02 24 22 29 5379 Breast Cancer 20210224225528 20220322220342
cfDNA detection may simplify breast cancer monitoring: study
In a study published recently in Science Advances, the researchers found that plasma cell-free DNA (cfDNA) contains high resolution, genome-wide binding estrogen receptors (ER) and FOXA1 profiles for breast cancer.
August 30, 2022
2021 02 24 22 29 5379 Breast Cancer 20210224225528 20220322220342
FDA clears Angle’s Parsortix breast cancer system
The FDA clearance is the first FDA product clearance to harvest cancer cells from a blood sample for subsequent analysis. This offers the prospect of a new era of personalized cancer care, according to the company.
July 27, 2022
2022 07 28 17 23 1016 Breast Biopsy Mammotome 400
Clinics begin adopting Genetic Technologies risk test
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
2022 04 18 13 42 3384 Dna Genome Gene Targeted 400
Artemis signs $250M deal for liquid biopsy tests with Datar
The contract gives Artemis DNA the exclusivity to commercialize and distribute the liquid biopsy tests Trucheck Pragma and Cancertrack in the U.S. and Vietnam. Trucheck Pragma is a noninvasive blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; Cancertrack is a cancer monitoring test that allows patients to evaluate response/resistance during treatment and monitor recurrence of cancer.
May 15, 2022
2017 09 14 23 05 1167 Cancer Cell 400
Previous Page
Page 2 of 11
Next Page